Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q2 2019 Net Income-$115.66K-$115.66KN/M vs Q2 2019 EPS Diluted-$0.52-$0.52— vs Q2 2019 Gross Profitderived$0−100.0%
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
Operating Income-$54,560N/M Operating Cash Flowderived-$329N/M ended Jun 30, 2020 · filed Aug 7, 2020 · 38 d after period end